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Background: Nigella sativa belonging to the Ranunculaceae family has been reported to use for thousands of years
as protective and curative traditional medicine against a number of diseases. GC-MS analysis of methanolic extract
(ME) and volatile oil (VO) extracted from Nigella sativa seed oil was performed by two different mass spectrometry
libraries, WIlEY8 and NIST05s. The cholesterol lowering and antioxidant actions of VO and ME fractions were
investigated in atherogenic suspension fed rats.
Methods: In this study, four groups of male Wistar rats were used: normolipidemic control (NLP-C), hyperlipidemic
control (HLP-C), methanolic extract (HLP-ME) and volatile oil treated (HLP-VO) groups for 30 days of duration. P
value < 0.05 was assumed as significant data in groups.
Results: Administration of atherogenic suspension to male Wistar rats for 30 days resulted in a marked increase of
plasma triglycerides and total cholesterol, and significant change in plasma lipoprotein levels along with a decrease
in antioxidant arylesterase activity in hyperlipidemic control (HLP-C) group. The oral feeding of 100 mg ME or 20
mg VO per rat/day effectively reduced the plasma triglycerides to near normal level, while high density lipoprotein
cholesterol and its subfraction along with arylesterase activity levels were significantly increased. The test fractions
elicited a significant decrease in hepatic HMG-CoA reductase activity. The fractions significantly blocked the ex vivo
basal and in vitro maximal formation of conjugated diene and malondialdehyde, and lengthened the lag times of
low density lipoprotein, small dense low density lipoprotein and large buoyant low density lipoprotein. ME
possessing ω-6 linoleic acid along with palmitic acid active compounds was more effective than VO extract
containing thymol and isothymol phenolic antioxidant compounds, thymoquinone phenolic compound common
to the both extracts, via reduction in hepatic HMG-CoA reductase activity as well as antioxidant mechanisms.
Conclusion: The both extracts especially, ME significantly improve cardiovascular risk parameters in treated rats,
and can be used in reactive oxygen species disorders such as cardiovascular diseases.
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The World Health Organization (WHO) has declared
that due to cardiovascular disease (CVD), the death toll of
people will reach approximately 23.6 million around the
world by 2030 [1]. It is well known that hypercholesterol-
emic patients are more prone to heart attack than normal
blood lipid profiles. According to the WHO report, con-
sumption of unhealthy diets, rich in fat, salt and free sugar,
and low in complex carbohydrates, fruits and vegetables
are responsible for CVD [2]. Diets rich in cholesterol pro-
duce free radicals, followed by oxidative stress and hyper-
cholesterolemia [3,4]. Oxidative stress is one of the factors
that causes rise in the level of blood cholesterol and it may
result in atherogenesis [5]. High concentration of LDL-C
in plasma is one of the major causes of coronary heart
disease (CHD) as evidenced by epidemiological studies [6].
In comparison to lb-LDL, sd-LDL is highly atherogenic be-
cause of the presence of properties like enhanced suscepti-
bility to oxidation, higher penetration in the arterial wall,
lower binding affinity to the LDL-receptor, and prolonged
plasma half life [7,8]. Hence, it will be focusing attention
on sd-LDL as a new precise and useful CHD marker
[9-11]. Blood cholesterol is recommended to be within
normal range to preserve normal cell functions. At
present, there are several methods known to control
blood cholesterol levels, including dietary fats, bile acids
sequestering agents and use of HMG-CoA reductase in-
hibitors. Among them, HMG-CoA reductase is the key
enzyme in the cholesterol biosynthesis pathway that could
be an important target of an inhibitor for managing blood
cholesterol levels [12].
Use of the modern drugs explores various drawbacks
that are expensive, beyond the reach of a majority of
the population of the world and multiple side effects.
Therefore, today drugs from indigenous sources should
be designed and suitable different combinations of such
drugs tested for therapeutic purposes, which posses min-
imal adverse effects and multiple targets in preventing and
curing diseases. A number of epidemiological studies have
been reported that plant foods carry a high quantity of
phenolic compounds, are effective against fatal chronic
diseases like cancer, neurodegenerative and CVD [13-15].
Such compounds show antioxidant properties. Their free
radical scavenging properties solely rely upon constituents
as well as synergistic interactions [16]. Various types of re-
active oxygen species (ROS) are generated in our body and
their removal must be continually done for the mainten-
ance of normal cellular functions. Phenolic compounds
(POH) deactivate various types of free radicals such as
hydroxyl radicals and peroxyl radicals (R•) by donating
hydrogen, which interrupts chain reactions:
R• þ POH→RHþ PO• Interruption reactionð Þ
PO•þPO•→POOP Stabilization reactionð ÞIn the above reactions, stabilization of phenoxyl radicals
(PO•) is possible through resonance and/or intramolecular
hydrogen bonding [17]. Thus, consumption of phenolic
compounds may be useful to the health. Recently, Nigella
sativa (NS) has been reported to possess multiple health
beneficial properties. Several studies have been reported
that methanolic extract (ME) [14], volatile oil (VO) [18]
from black cumin and their principal active constituent
thymoquinone [19], show antioxidant properties. Phenolic
compounds such as thymol, isothymol have been shown
to have antioxidant actions [20], and essential fatty acid,
ω-6 linoleic acid [21] or ω-6 linoleic acid with palmitic
acid have hypolipidemic property [22].
Elevated levels of TG and TG rich VLDL, these two
parameters are regarded as risk factors for atheroscler-
osis [23,24], while an elevated level of plasma HDL-C is
considered beneficial to the health because these are in-
versely correlated with the risk factor for atherosclerosis
[25]. In agreement with these concepts, drugs that cause
reduction of TG, TG rich VLDL and increase in HDL
would be helpful in decrease in the morbidity and mor-
tality from CAD [25,26]. HDL is assumed a key lipopro-
tein that helps lipid removal from macrophage foam
cells in the arterial wall, and thus protects LDL oxida-
tion. Several studies have been performed using albino
Wistar rats as experimental atherosclerosis model, and
they found it suitable and effective model to be used in
condition of hypercholesterolemia and atherosclerosis
[27,28]. In the present study, we have performed gas
chromatography (GC) analysis of the ME and VO, frac-
tionated from NS seed oil and identified their constitu-
ents by using two different mass spectrometry (MS)
libraries. In order to understand the mechanisms of lipid
lowering actions of these test fractions, we explored the
hepatic HMG-CoA reductase activity as well as their
protective effect on HDL-linked arylesterase activity, in
rats for 30 days. Further, the antioxidant protection of the
test fractions afforded to LDL and its density subfractions,
sd-LDL and lb-LDL, from in vivo and Cu2+-catalyzed
in vitro oxidation was investigated. This objective was
achieved by measuring ex vivo basal and in vitro maximal
CD formations and lag times, as well as ex vivo basal and
maximal production of MDA in LDL, sd-LDL and lb-LDL
lipoproteins isolated from plasma of experimental animals.
Materials and methods
Materials
Export quality, edible Nigella sativa (NS) seed oil, was
bought from a local store. Phenyl acetate was pro-
cured from Sigma-Aldrich Inc. USA. Highly purified
thiobarbituric acid and hydroxylamine hydrochloride
were purchased from HiMedia Laboratories Pvt. Ltd.
(Mumbai, India), while phosphotungstic acid was bought
from Loba Chemie (Mumbai, India). And HMG-CoA was
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purchased from United States Bioch. Corp., USA, while
sodium dodecyl sulfate was obtained from Bio-Rad
Laboratories USA. Triglycerides assay kit for determin-
ation of triglycerides was procured from Autospan Kit
SPAN Diagnostics (New Delhi, India). Other chemicals and
reagents were used in this research of analytical grade.
Preparation of methanolic extract (ME) and volatile oil
(VO) extracts from NS seed oil
The ME fraction, used in the present study, was extracted
by stirring 10 g of the NS seed oil with 100 ml of metha-
nol for 100 min at ambient temperature. The methanol
layer was removed, and then evaporated at 45°C. The VO
fraction was extracted from NS seed oil by steam distilla-
tion. The procedure is essentially the same as described
for the isolation of VO extract from NS seeds [29] with
minor modification. Briefly, 400 ml of distilled water was
added to a distillation flask containing 12 g of NS seed oil,
and the temperature was set to the boiling point. The
process of distillation was continued until about 150 ml of
the distillate containing VO was collected in a dark glass
bottle. The distillate was extracted with 50 ml of diethyl
ether, moisture was removed by the addition of anhydrous
sodium sulphate and the resultant ether extract was evap-
orated at 40°C. The ME and VO extracts thus obtained
were stored under nitrogen in dark colored bottles at 4°C.
GC-MS analysis
GC-MS analyses of ME and VO extracted from NS oil were
performed by GCMS (QP2010 plus system Shimadzu).
Separation was carried out at chromatograph column of
SLB60m× ID 0.25 mm× thickness 0.25 μm. Column oven
temperature was initially set at 70°C for 2min, which was
increased to 310°C at the rate of 5°C per min with 20 min
hold. The carrier gas, helium was used with a flow of 1.21
ml per min. The split ratio was adjusted to 30.0. Injector
temperature was adjusted at 270°C. Ionization voltage was
70 eV. The constituents present in the samples were identi-
fied by matching their mass spectra with two mass spectra
libraries, namely WIlEY8.LIB and NIST05s.LIB. The soft-
ware of the system determined relative percentage amount
of the compounds that exist in the both samples.
Animals and treatments
The Board of Studies of the Biochemistry Department and
the Animal Ethics Committee of J.N. Medical College,
A.M.U., Aligarh, where the present research work was
performed, approved the experimental study. Healthy
male Wistar albino rats, weighting 180–210 g from inbred
colony maintained by central animal facility of J.N. Medical
College, were allowed free access to standard rat chow
and water. Ten percent ME and 2% VO suspensions
were prepared by dissolving in DMSO (12.5%) andthen homogenized with saline. The rats were divided
into the following groups:
Normolipidemic control (NLP-C): This group of animals
containing five rats was orally administered 1 ml solution
of saline containing 12.5% DMSO, twice 0.5 ml each
in the morning and evening per rat per day for 30 days
of duration.
Hyperlipidemic control (HLP-C): For the induction of
hyperlipidemia, before the administration of 1.0 ml athero-
genic suspension, this experimental group received 1.0 ml
of saline containing 12.5% DMSO, twice 0.5 ml each in the
morning and evening per rat per day for 30 days.
Hyperlipidemic methanolic extract (HLP-ME): One
milliliter of 10% ME suspension was given to the rats,
before the administration of 1.0 ml of atherogenic sus-
pension, twice 0.5 ml each in the morning and evening
per rat per day for 30 days.
Hyperlipidemic volatile oil (HLP-VO): One milliliter
of 2% VO suspension was administered, before the ad-
ministration of 1.0 ml of atherogenic suspension, twice
0.5 ml each in the morning and evening per rat per day
for 30 days.
As in previous studies, ME and VO were taken at dose
of 810 mg and 400 mg/day/kg body weight of male
Wistar rats, respectively [30,31]. The LD50 of ME was
not found at four different doses, 6, 9, 14 and 21 g/kg,
and further no hepatic toxicity of ME at 6 g/day/kg body
weight of mice was reported [32], and the LD50 of VO
was found to be 0.5 ml/day/kg body weight of male albino
mice [33]. So based on these reports, we took single, safe
and effective dose of ME and VO.
Plasma separation from blood
At the end of the experiment, rats were anaesthetized
and blood was taken out by cardiac puncture from over-
night fasted rats in each group. The blood was collected in
heparinized tubes. After incubation at 4°C for 2–3 h, blood
samples were centrifuged at 2,500 rpm for 30 min. Plasma
was aliquoted and stored at 4°C for future use.
Low density lipoprotein (LDL), small dense (sd)-LDL and
large buoyant (lb)-LDL fractionation
Basically the precipitation method for plasma LDL isolation
as described by Wieland and Seidel [34] was employed.
Briefly, the precipitation buffer consisted of 64 mM
trisodium citrate, pH 5.05, plus 50,000 IU/L heparin. Prior
to LDL precipitation, plasma samples and precipitation
reagent were allowed to equilibrate to room temperature.
Then 1.0 ml of plasma was added to 7.0 ml of heparin-
citrate buffer, mixed properly, and then it was allowed to
stand for 10 min at 22°C. Then it was centrifuged at 1,500
rpm for 10 min at 22°C. The pellet thus obtained was
resuspended in 1.0 ml of 0.1 M sodium phosphate buffer
saline, pH 7.4. Hirano et al. [10] described the isolation of
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isolated LDL which is based on the two-step procedure
quantifying sd-LDL from serum by heparin-Mg2+ pre-
cipitation. In our modified method for the isolation of
sd-LDL and lb-LDL from plasma LDL, 0.1 ml precipi-
tation reagent solution prepared by taking 15 IU of
heparin and 90 mM MgCl2 was added to 0.1 ml of LDL.
The sample was properly mixed, then incubated at 37°C for
10 min. Each sample was then incubated in an ice-bath for
15 min. Finally, each sample was centrifuged at 10,000 rpm
for 15 min at 4°C. The upper supernatant and lower
portions of the samples containing sd-LDL and lb-LDL,
respectively were carefully removed and saved. The lb-LDL
fraction as pellet was dissolved in 0.1 M sodium phosphate
buffer saline, pH 7.4. Appropriate quantities of LDL,
sd-LDL and lb-LDL fractions were taken out for fur-
ther analysis.
Isolation of plasma very low density lipoprotein (VLDL)
Plasma VLDL was isolated as described by Bachorik and
Albers [35]. Briefly, for the isolation of VLDL, 0.075 volume
of 10% sodium dodecyl sulfate solution was added to 1
volume of plasma, and then properly mixed. Afterwards, it
was incubated for 2 h at 37°C and finally centrifuged at
10,000 rpm for 10 minutes at room temperature. At the
top of the centrifuge tube, VLDL pellicle was appeared.
The supernatant was carefully removed. The residue of
VLDL pellicle was dissolved in one volume of 1% sodium
dodecyl sulfate by warming at 37°C.
Isolation of plasma high density lipoprotein cholesterol
(HDL-C) and HDL3-C subfraction
High density lipoprotein cholesterol from plasma was
isolated by the method of Kostner [36] and HDL3-C
subfraction of HDL-C was isolated by the procedure as
described by Bachorik and Albers [35]. In brief, 0.2 volume
of phosphotungstic acid and magnesium chloride (1:1)
was added to 1 volume of plasma, and then instantly
and properly mixed. It was finally centrifuged for 10 min
at 12,000 rpm at room temperature. The clear supernatant
was carefully removed and thus represented the plasma
HDL-C. For HDL-C fractionation, reagent ‘X’ was prepared
by mixing 1 volume of 40 g/L dextran sulfate, Ph 7.0
with 3 volumes of 2M MgCl2.6H2O, Ph 7.0. To fraction-
ate HDL-C, 0.1 volume of reagent ‘X’ was added to one
volume of HDL-C and mixed immediately. Then it was
centrifuged at 5,000 rpm for 30 min at 4°C. Aliquots of
clear supernatant were used for HDL3-C analysis. HDL2-C
was then calculated as the difference between HDL-C and
HDL3-C concentration.
Determination of plasma and lipoprotein cholesterols
Plasma total cholesterol, VLDL, LDL and HDL lipopro-
tein cholesterols and their fraction cholesterols weredetermined as previously stated by Ahmad and Beg
[37] in detail.Determination of plasma triglycerides
Triglycerides present in plasma were determined by
enzymatic kit, based on a modified Trinder color reac-
tion, which produces fast, linear, and end point reac-
tion [38]. The intensity of the color produced of the
triglycerides in the plasma samples was measured at
500 nm in a Beckman DU 640 spectrophotometer. Triolein
was used as standard to calculate triglycerides concentra-
tion in plasma samples.Determination of hepatic HMG-CoA reductase activity
HMG-CoA reductase enzyme activity in liver homogen-
ate was assayed indirectly by employing the method of
Rao and Ramakrishnan [39]. Briefly, fresh 10 g liver was
homogenized in 90 ml of saline arsenate. Then equal
volume of 10% liver homogenate and 5% perchloric acid
(5 ml each) was taken out and thoroughly mixed, and
kept for 5 min at room temperature. Afterwards, it was
centrifuged at 2,000 rpm for 10 min. Half milliliter of
freshly prepared 1 M aqueous hydroxylamine hydro-
chloride was mixed with one ml of the supernatant
obtained after centrifugation. For determination of
HMG-CoA reductase, 0.5 ml of alkaline hydroxylamine
hydrochloride was added and properly mixed. Then it
was allowed to incubate for 5 min at room temperature.
Afterwards, 1.5 ml of 0.616 M ferric chloride solution
consisted of 5.2% trichloroacetic acid prepared in 0.65
N HCl was added to the above sample and thoroughly
mixed, and incubated for 10 min at room temperature.
Absorbance was recorded at 540 nm against a reagent
blank in a Beckman DU 640 spectrophotometer.Determination of plasma arylesterase antioxidant enzyme
activity
Plasma arylesterase antioxidant enzyme activity was
essentially assayed by the method of Ayub et al. [40].
Phenyl acetate was used as the substrate. The reaction
mixture consisted of 100 mM tris buffer, pH 8.0, 1 mM
CaCl2, 1 mM phenyl acetate and suitable aliquots of
plasma sample. After 5 min of preincubation period of
the samples, the reaction was started by adding the
phenyl acetate and incubated for different time intervals
at 25°C. Absorbance of initial rates of hydrolysis was
determined spectrophotometrically at 270 nm against a
reagent blank, while nonenzymatic hydrolysis of phenyl
acetate was subtracted from the total rate of hydrolysis.
The molar extinction coefficient of 1.31 × 103 M-1 cm-1
was used to calculate the arylesterase enzyme activity
in the plasma sample [41].
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susceptibility of LDL, sd-LDL and lb-LDL to oxidation
The ex vivo and in vitro Cu2+-mediated susceptibility of
LDL, sd-LDL and lb-LDL to oxidation was determined
by as described by Esterbauer et al. [42] and Esterbauer
et al. [43]. Before oxidation studies of lipoprotein fractions
by determining the lag phase of conjugated diene forma-
tion were dialyzed against 10 mM phosphate buffer saline
(PBS), pH 7.4, for 12 h. At different time of interval of oxi-
dation, 100 μg of LDL, sd-LDL or lb-LDL dissolved in 1.0
ml of PBS was added to 0.5 mM EDTA, and then mixed,
afterward stored at 4°C and used for the assessment of
conjugated diene formation. In another set of zero time
ex vivo oxidation, one ml aliquot of each sample was
added to a tube carrying 0.5 mM EDTA, pH 7.4, for the
determination of levels of conjugated diene formation in
the lipoprotein isolated from plasma. Then, lipoprotein
fractions, LDL, sd-LDL and lb-LDL from plasma were
added to CuSO4 making final concentration of 5 μM and
incubated at 37°C. Durations of 2 h for LDL and lb-LDL,
and 30 min for sd-LDL were taken for their oxidation.
The conjugated diene formation in plasma lipoproteins
was quantified by recording absorbance at 234 nm in a
Beckman DU 640 spectrophotometer. Molar extinction
coefficient of 2.52 × 104 M-1 cm-1 was used to calculate
conjugated diene formation, and expressed as nmole
malondialdehyde (MDA) equivalent per mg LDL, sd-LDL
or lb-LDL protein.
Niehaus and Samuelsson [44] described a method to
determine MDA content in LDL, sd-LDL and lb-LDL
isolated from plasma. In Brief, 2 ml of trichloroacetic acid
(15%)-thiobarbituric acid (0.375%)-hydrochloric acid
(0.25 N) reagent was added to 0.3 ml of LDL, sd-LDL
and lb-LDL, and mixed properly. The solution was kept
in a boiling water bath for 15 min. Then flocculent pre-
cipitate was removed by centrifugation at 1000 rpm for
10 min. The absorbance of the samples was monitored
at 535 nm against a sample blank. The MDA concentra-
tion of the lipoprotein samples was determine by using
a molar extinction coefficient (1.56 × 105 M-1 cm-1).
Protein estimation
The method of Bradford [45] was used for protein es-
timation of plasma lipoproteins and liver using bovine
serum albumin as standard. Suitable aliquots of the
samples were precipitated with 10% trichloroacetic acid.
The obtained protein pellets were dissolved in 0.5 N
NaOH, then suitable portions of the samples were used
for protein quantification.
Statistical analysis
One way analysis of variance (ANOVA) was employed
for statistical analysis of the data, then Tukey’s Kramer




Thirty compounds in methanolic extract (ME) were
identified by GC-MS analysis and listed in Table 1. As
shown in Table 1, the compounds that were examined
in ME, consists of a mixture of terpenes, saturated and
unsaturated fatty acids along with certain ester form
of compounds. The major compounds were limonene
(1.13%), butylated hydroxytoluene (2.44%), thymoquinone
(2.64%), palmitic acid (2.77%), phytol (2.82%) and glycerol
1-monolinolate (3.99%). The most dominant compound, an
essential fatty acid was identified as linoleic acid (75.00%).
Forty six compounds were identified in volatile oil (VO)
extracted from NS seed oil by steam hydrodistillation
(Table 2). VO extract consisted of a number of classes
of compounds, were various types of nonterpenoid
and terpenoid hydrocarbones. The major representa-
tive compounds of VO were p-cymene (3.81%), p-tert-
butylpyrocatechol (4.28%), (+)-trans, trans-5-caranol
(7.83%), 4-terpineol (10.55%), thymoquinone (13.53%)
and thymol (31.98%). Thymol represented highest quantity.
Other pharmacological minor compounds identified
in VO were isothymol (also called carvacrol), carvone,
copaene and limonene oxide. Chromatograms of ME
and VO test fractions were given as Additional file 1:
Data S1 and Additional file 2: Data S2, respectively.
Body weight, food consumption and weight of liver
The average body weights of normolipidemic rats were
increased from 223 g to 279 g after 30-days duration.
The body weight of HLP-C group was increased by 20%
when compared to NLP-C rats after giving atherogenic
suspension for 30 days. In treated groups with ME and
VO for 30-days duration, the final body weights were
significantly reduced by 28% and 25%, respectively
after comparing to HLP-C control group. In the case of
the average diet consumption in the all control and
treated groups, there were no significant changes observed
(data not shown). Average liver weights in HLP-C rats,
were increased by 20% when compared to normolipidemic
rats, while in the both treated groups, the liver weights were
5.48 and 5.43 g with highly significant reduction (Table 3).
Impact on plasma and lipoprotein lipids of rats
Figure 1 demonstrates that administration of atherogenic
suspension to rats resulted in significant increments by 105%
(TG), 168% (TC), 222% (non-HDL-C, equivalent to TC
minus HDL-C), 105% (VLDL-C) and 207% (LDL-C) with
substantial decrease by 6% (HDL-C) and 13% (HDL2-C),
when compared to the values of normolipidemic rats.
Pretreatment with 100 mg ME or 20 mg VO per rat per
Table 1 Chemical composition of methanolic extract (ME) from Nigella sativa seed oils
Peak no. Compounds Retention time Area%
1 Limonene 11.138 1.13
2 Dihydrocarveol 13.709 0.08
3 4-Carvomenthenol 15.445 0.03
4 Thymoquinone 17.529 2.64
5 Isothymol 18.828 0.34
6 Verbenone 20.507 0.15
7 Humulen-(v1) 21.989 0.23
8 Butylated hydroxytoluene 24.380 2.44
9 Acetovanillone 25.395 0.94
10 3-Methoxy-4,5,6-trimethylphenol 28.170 0.05
11 4-(Methylthio)acetophenone 28.265 0.03
12 Myristic acid 29.861 0.06
13 Palmitic acid, methyl ester 33.175 0.10
14 (Z)6-Pentadecen-1-ol 34.024 0.53
15 Palmitic acid 34.248 2.77
16 Citronellyl butyrate 34.376 1.05
17 Oleic acid, methyl ester 36.567 0.49
18 Phytol 36.747 2.82
19 Linoleic acid 38.435 75.00
20 beta-Monolinolein 42.187 0.45
21 Benzedrex 42.672 0.35




24 Linoleic acid trimethylsilyl esterI 46.040 1.15
25 Glycerol 1-monolinolate 46.443 3.99
26 Acetylhydroquinone 51.604 0.14
27 Squalene 53.043 0.23
28 Stigmasterol 55.298 0.11
29 gamma-Sitosterol 56.448 0.21
30 Olealdehyde 58.703 0.17
100.00
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resulted in significant changes in TG (−50% or −32%),
TC (−60% or −61%), non-HDL-C (−69% or −67%),
VLDL-C (−49% or −32%), LDL-C (−68% or −67%) and
HDL-C (+23% or +12%), HDL2-C (+51% or +21%) and
HDL3-C (+11% or +8%), respectively, when compared
to the corresponding values in HLP-C rats.
Impact on HDL-linked arylesterase activity and LDL-C:
arylesterase ratio
The data presented in Table 4, was basically obtained from
Figure 1. In the lipidemic oxidative stress HLP-C control
group, the value of arylesterase was significantly decreased
by 21% coupled with increase in LDL-C:arylesterase ratioby 287% when compared to values in NLP-C rats. After
treatment with the test fractions ME or VO, substantial
restorations in arylesterase activity, and LDL-C:arylesterase
ratio in the range of 102%-111%, were obtained.
Impact on hepatic 3-hydroxy, 3-methyl glutaryl CoA
reductase activity
A rate limiting enzyme, hepatic 3-hydroxy, 3-methyl
glutaryl CoA reductase (HMG-CoA reductase) activity
was significantly reduced by 32% in HLP-C group,
when compared to NLP-C value. Further, decline in
the values of treated rats with ME or VO was observed
by 44% or 42%, respectively, in comparison to NLP-C
value (Table 5).
Table 2 Chemical composition of volatile oil (VO) from






1 p-Cymene 11.008 3.81
2 beta.-Terpineol 12.233 0.48
3 Dihydrocarveol 13.044 0.50
4 Isothujol 13.144 0.61
5 (+)-trans, trans-5-Caranol 13.744 7.83
6 1-Terpinenol 13.818 0.23
7 cis-beta-Terpineol 14.332 0.17
8 Thujol 15.029 0.14
9 4-Terpineol 15.507 10.55
10 p-Cymen-8-ol 15.639 1.62
11 Terpineol 15.830 0.38
12 Allethrolone 16.156 0.21
13 Methoxycitronellal 16.615 0.12
14 Carvone 17.344 0.26
15 Thymoquinone 17.535 13.53
16 trans-Carveol 17.646 0.53
17 Linalyl anthranilate 17.766 0.27
18 Carvenone 17.858 0.14
19 Pichtosin 18.476 0.79
20 Thymol 18.565 31.98
21 Isothymol 18.961 1.64
22 trans,trans-2,4-Decadienal 19.257 0.31
23 Copaene 20.445 1.03
24 Limonene oxide 20.892 0.34
25 (+)-Sativen 21.892 0.12
26 Longifolene-(V4) 22.027 7.23
27 Methyl 2,5-octadecadiynoate 23.602 0.14
28 2-Tridecanone 23.750 0.63
29 beta.-Farnesene 24.249 0.16
30 (-)-Isoledene 24.832 0.16
31 p-tert-Butylpyrocatechol 25.421 4.28
32 beta-Pinene oxide 26.564 0.21
33 1-Cyclododecyl-ethanone 28.064 0.32
34 11-Dodecen-2-one 28.486 0.33
35 Epiglobulol 28.602 0.72
36 5-Tetradecen-1-ol, acetate, (Z)- 29.969 0.14
37 2,4,5-Trimethoxy benzoic acid 30.390 0.96
38 Palmitic acid, methyl ester 33.191 0.40
39 9-Octadecyne 34.033 0.56
40 Rimuen 34.317 1.31
41 Cephrol 34.378 1.24
42 Preg-4-en-3-one, 12,17-dihydroxy-20-nitrilo- 35.197 0.47
43 Methyl linoleate 36.474 0.97
Table 2 Chemical composition of volatile oil (VO) from
Nigella sativa seed oils (Continued)
44 Methyl oleate 36.564 0.37
45 Citronellal 36.700 1.70
46 Vellerdiol 37.558 0.10
100.00
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of LDL and its subfractions sd-LDL and lb-LDL and their
lag time
As data in Figure 2 demonstrate that maximal conjugated
diene (CD) formation from LDL was significantly increased
by 299% in comparison to basal value in NLP-C rats.
Feeding of atherogenic suspension to HLP-C rats led
to significant increase in ex vivo basal CD formation of
LDL, sd-LDL and lb-LDL by 52%, 55% and 20%, respect-
ively in comparison to NLP-C rats. After treatment with
ME or VO, significant reduction in basal CD formation of
LDL and its subfractions, sd-LDL and lb-LDL, was seen
by −22% or −18%, -32% or −28% and −14% or −8% when
compared to the corresponding values in HLP-C rats. In
comparison to basal CD values of LDL, sd-LDL and lb-
LDL in NLP-C, the respective maximal CD values were
increased by 299%, 305% and 290%. After treatment
with ME or VO, a substantial decrease in CD product
of LDL, sd-LDL and lb-LDL by 32% or 22%, 40% or
30% and 13% or 8%, respectively was observed when
compared to atherogenic suspension fed control rats.
In the case of lag phase of LDL, sd-LDL and lb-LDL
lipoproteins, a substantial decrease by 41% (53 min),
35% (11 min) and 29% (36) in the stressed control group
of rats was seen, when compared to the normolipidemic
control rats. Similar to CD values, lag phase of the treated
groups was significantly restored and increased close to the
corresponding normal values in NLP-C rats (Figure 2).Impact on Cu2+-induced generation of malondialdehyde
in plasma LDL, sd-LDL and lb-LDL
As in Table 6, basal malondialdehyde (MDA) formation
of LDL, sd-LDL and lb-LDL was substantially increased
by 106% (6.47 nmole/mg protein), 71% (8.05 nmole/mg
protein) and 61% (6.18 nmole/mg protein), respectively
in HLP-C rats when compared to the corresponding values
in NLP-C rats after 30-days duration. In comparison to
MDA values of HLP-C rats, the maximal MDA values of
LDL, sd-LDL and lb-LDL were significantly increased by
81%, 66% and 32%, respectively. After treatment with the
test fractions, ME or VO a significant basal restoration
close to normal values was observed as 78% or 65%, 81% or
68%, and 80% or 72% and maximal restoration as 83% or
72%, 84% or 70% and 93% or 87%, respectively.
Table 3 Average body and liver weights of rats during 30 days of treatment with ME and VO fractions
Group Body weight per rat (g) Liver weight per rat (g)
Prior to treatment Post treatment
NLP-C 233.30 ± 20.8 278.60 ± 16.72 5.44 ± 0.22
HLP-C 22.00 ± 14.71 334.50 ± 14.50 (+20.06%)α 6.51 ± 0.01 (+19.65%)α
HLP- ME 221.25 ± 13.14 240.25 ± 9.74 (−28.18%)b 5.48 ± 0.03 (−15.82%)b
HLP-VO 220.00 ± 10.80 250.75 ± 4.85 (−25.04%)b 5.43 ± 0.07 (−16.59%)b
Each value is mean ± SD from 4 rats in each group except NLP (n = 5). NLP-C, normolipidemic control fed 1 ml saline/rat/day; HLP-C, hyperlipidemic control given
1 ml of saline before the feeding of 1 ml suspension containing 5 mg cholesterol, 30 mg coconut oil and 2.5 mg cholic acid /rat/day; whereas rats in HLP-ME,
HLP-VO were fed 1 ml of 100 mg ME, 20 mg VO prior to administration of 1 ml of the above atherogenic suspension /rat/day for 30 days. Note: All the values in
NLP-C and HLP-C control groups in this manuscript were already presented in our previously published article [37]. The values were statistically significant from
NLP-C at ap < 0.05 and HLP-C at bp < 0.05.
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Methanolic extract (ME) and volatile oil (VO) extracted
from NS seed oil containing different phenolic, and
terpenoid compounds along with other pharmaceutical
compounds exert their effects on hypercholesterolemic
rats through multiple mechanisms. In this study, we
investigated hypolipidemic and antioxidant actions of ME
and VO in atherogenic suspension fed rats. Administration
of atherogenic suspension to rats containing 30 mg coconut
oil, 5 mg cholesterol and 2.5 mg cholic acid per day/rat forFigure 1 Protective effects of ME and VO extracts of NS oil on
plasma TG, TC, non-HDL-C (TC-HDL-C), VLD-C, LDL-C, HDL-C,
HDL2-C and HDL3-C subfractions. NLP-C, normolipidemic control
fed 1 ml saline/rat/day; HLP-C, hyperlipidemic control given 1 ml of
saline before the feeding of 1 ml suspension containing 5 mg
cholesterol, 30 mg coconut oil and 2.5 mg cholic acid/rat/day;
whereas rats in HLP-ME and HLP-VO were fed 1 ml of 100 mg ME or
20 mg VO, prior to administration of 1 ml of the above atherogenic
suspension/rat/day for 30 days. Each value represents mean ± SD
from pooled plasma samples in each group. The values of HLP-C
control groups were statistically significant from NLP-C groups
(p < 0.05), the values of treated groups were significantly different
from HLP-C groups (p < 0.05), and the values between the treated
groups were also significant (p < 0.05).30 days exerted significant increments in the body and liver
weights in HLP-C group of rats. Such gains in the weights
were apparently owing to the deposition of lipid contents
in the body, especially in the liver. Feeding of cholic acid, a
component of atherogenic suspension helped in the intes-
tinal absorption of the both cholesterol and fatty acids. This
could be one of the reasonable factors that could explain
the weight gains in the average body as well as the liver
of the rats. Thirty day feeding of ME and VO suspen-
sions significantly reduced the body weight along with
liver weight, possibly by reducing the accumulation of
fatty acids in adipose tissue of the treated rats, when
compared to normolipidemic rats (Table 3).
As seen in HDL-C rats (Figure 1), increases in plasma
TG and VLDL-C concentrations may be due to high
production of VLDL with decreased clearance rate of
TG as reported in hepatic β-VLDL secretion in choles-
terol fed rabbits [46]. Presence of high concentration
of plasma VLDL-C it may also lead to decreased pro-
duction of antiatherogenic HDL because of the low
availability of phospholipid remnants for its formation
from VLDL and decline in the activity of lecithin chol-
esterol:acyltransferase as reported in several published
reports. Treatment with the test fractions to the rats
led to significant reduction in the levels of plasma TG,
TC, VLDL-C, LDL-C and non-HDL-C, and antiatherogenicTable 4 Effect of methanolic extract (ME) and volatile oil
(VO) fractions on plasma arylesterase activity and the





NLP-C 665.15 ± 4.60 0.9220 × 10-3 ± 0.180 × 10-5
HLP-C 527.34 ± 4.73 (−20.71%)a 3.5682 × 10-3 ± 0.225 × 10-5 (+287.00%)a
HLP- ME 711.61 ± 4.70 (+34.94%)b 0.8338 × 10-3 ± 0.170× 10-5 (−76.63%)b
HLP-VO 680.57 ± 5.20 (+29.05%)b 0.9020 × 10-3 ± 0.180 × 10-5 (−74.72%)b
†LDL-C (mg/ml) values are taken from Figure 1. Each value represents mean ±
SD from pooled plasma samples in each group. The values were statistically
significant from NLP-C at ap < 0.05 and HLP-C at bp < 0.05, and the values
between the treated groups were also significant (p < 0.05).
Table 5 In vivo modulation effect of ME and VO fractions
on hepatic HMG-CoA reductase activity in atherogenic
suspension fed rats
Group HMG-CoA reductase activity†
NLP-C 28.90 ± 0.04
HLP-C 19.72 ± 0.07 (± 31.76%)α
HLP- ME 16.33 ± 0.06 (−43.49%)a
HLP-VO 16.74 ± 0.05 (−42.07%)a
† Its activity is expressed as percent of nmoles of HMG-CoA to mevalonate
formed per mg liver protein. Each value represents mean ± SD from pooled
liver samples in each group. The values were highly significant from NLP-C at
ap < 0.001, and the values between the treated groups were also statistically
significant (p < 0.05).
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http://www.lipidworld.com/content/12/1/86HDL-C along with its subfractions were significantly
increased, and finally restoration of these altered lipopro-
teins were gained to near or above normal values. In this
observation of results, ME had proven itself as higher
potential agent than VO. Arylesterase is an important
plasma HDL-linked antioxidant enzyme, protecting LDL
from oxidative modification. LDL-C:arylesterase ratio,
a good marker is used in hyperlipidemia. Thus, it is
clear from the discussion that in lipidemic oxidative
stress arylesterase, and LDL-C:arylesterase ratio wereFigure 2 In vivo and in vitro Cu2+-catalyzed oxidation of LDL
and its sd-LDL and lb-LDL subfractions from plasma of
hyperlipidemic rats after 30 days of ME and VO treatment.
Here, expression of the conjugated diene (CD) values is as nmole
malondialdehyde (MDA) equivalents/mg protein. The basal CD
values show the status of oxidized LDL, and its subfractions sd-LDL
and lb-LDL in vivo. After 2 h of incubation for lipoproteins, LDL,
lb-LDL, and 30 min of incubation for sd-LDL with CuSO4, their
maximal CD formation values were determined. The interval between
the intercept of the tangent of the slope of the curve with the time in
min is known as lag time. Each value represents mean ± SD from
pooled plasma samples in each group. The values of HLP-C control
groups were statistically significant from NLP-C groups (p < 0.05), the
values of treated groups, HLP-ME and HLP-VO were significantly
different from HLP-C groups (p < 0.05), and the values between the
treated groups were also significant (p < 0.05).substantially changed apparently due to prooxidant effect
against oxidation of LDL and ultimately malondialdehyde
(MDA/TBARS) production. It is also evident from the
discussion; decrease in arylesterase was consistent with
HDL-C decrease and vice versa. Treatment with ME or
VO to rats, restoration of arylesterase and HDL-C along
with its subfractions was higher to normal values, and
therefore arylesterase may play an important role in
the antioxidation, anti-inflamatory or antiatherosclerotic
properties [47].
An important rate-limiting enzyme, HMG-CoA reduc-
tase was suppressed in HLP-C rats by feeding atherogenic
suspension (Table 5). Activity of HMG-CoA reductase in
HLP-ME and HLP-VO rats was further reduced that
apparently involved two related mechanisms as reported
by Al-Naqeep et al. [48], in thymoquinone rich fraction
treated rats: suppression of hepatic HMG-CoA reductase
mRNA expression and increment in LDL receptor gene.
Such regulations could clearly explain the hypolipidemic
properties of ME and VO test factions that contained
thymoquinone (2.64%) and (13.53%), respectively. Other
compounds present in these test fractions may exert inde-
pendently or synergistically (Tables 1 and 2) on lipidemic
oxidative stress in rats. Atherogenic suspension induced
oxidative stress and increased susceptibility of lipoproteins
and other membrane lipids to oxidation in rats. Oxidative
stress was result from equilibrium loss between antioxidant
and oxidant systems. As in Figure 1 and Table 4, it is clearly
evident that antioxidant HDL-linked arylesterase was
significantly decreased and increased cholesterol content
of LDL and LDL-C:arylesterase ratio in HLP-C rats com-
pared to NLP-C rats. Increased LDL-C, low HDL-C and
elevated TG levels (lipid triad) coupled with decrease in
HDL-linked arylesterase in lipidemic oxidative stress rats
are reflected in CD and MDA productions in LDL and its
subfractions sd-LDL and lb-LDL. Sd-LDL subfraction of
LDL is assumed comparatively higher inducer than lb-LDL
for proatherogenic process in the vessel wall of humans
with hyperlipidemia, similar to atherogenic lipoprotein
phenotype pattern B subjects [49,50]. Because of several
oxidizable properties were attributed to it, such as reduced
content of free cholesterol and antioxidant, increased
amount of more oxidizable polyunsaturated fatty acids
[50,51]. Thus, more conjugated diene (CD) formation in
sd-LDL than lb-LDL was seen in the both basal and max-
imal CD productions in lipidemic induced hyperlipidemic
rats. Further, small lag time of sd-LDL of HLP-C rats com-
pared to respective values in lb-LDL shows higher prone to
oxidative damage. This could also reflect in increased
Cu2+-induced ex vivo basal and maximal MDA production.
Administration of lipidemic stress in rats with the test
fractions, ME and VO resulted in the restoration of CD
and MDA levels of LDL and its subspecies sd-LDL and
lb-LDL to an average value of 85%, when compared to
Table 6 In vivo and in vitro Cu2+-induced generation of malondialdehyde (MDA) in plasma LDL, sd-LDL and lb-LDL
from rats after 30 days of methanolic extract (ME) and volatile oil (VO) treatment
Group Malondialdehyde†
LDL Sd-LDL Lb-LDL
Basal Maximal Basal Maximal Basal Maximal
NLP-C 3.14 ± 0.05 26.69 ± 0.11 (+750.00%) 4.71 ± 0.02 33.02 ± 0.09 (+601.06%) 3.83 ± 0.08 24.73 ± 0.05 (+549.69%)
HLP-C 6.47 ± 0.04 (+106.05%)a 48.40 ± 0.09 (+81.31%)a 8.05 ± 0.06 (+70.91%)a 55.60 ± 0.05 (+66.38%)a 6.18 ± 0.07 (+61.35%)a 32.68 ± 0.06 (+32.14%)a
HLP- ME 4.05 ± 0.08 (−37.40%)b 32.02 ± 0.06 (−33.84%)b 5.78 ± 0.05 (−28.19%)b 39.37 ± 0.06 (−29.19%)b 4.79 ± 0.09 (−22.49%)b 26.73 ± 0.07 (−18.20%)b
HLP-VO 4.80 ± 0.06 (−25.81%)b 36.98 ± 0.03 (−23.59%)b 6.92 ± 0.05 (−14.03%)b 47.08 ± 0.07 (−15.32%)b 5.30 ± 0.04 (−14.23%)b 28.30 ± 0.05 (−13.40%)b
†The values are expressed as nmole/mg protein. The basal MDA values in the table show the in vivo status of oxidized LDL, and its subfractions sd-LDL or lb-LDL. In the case
of maximal MDA values of the lipoproteins (LDL and lb-LDL oxidation) were achieved after 2 h of incubation with CuSO4, whereas for sd-LDL maximal values were obtained
after 30 min. Each value represents mean± SD from LDL, sd-LDL and lb-LDL subfractions, isolated from pooled plasma samples in each group. The values were statistically
significant from NLP-C at ap< 0.05 and HLP-C at bp< 0.05, and the values between the treated groups were also significant (p< 0.05).
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apparently through radical scavenging properties of the
test factions [14,18]. Overall, hypolipidemic and antioxidant
properties of ME were greater than VO in these stressed
rats. Such effects of the test fractions are deciphered to
indicate that the ME and VO strongly inhibit peroxidation
of the molecules or resulted in elimination of the react-
ive toxic intermediates initiated by free radicals, thus
preventing or delaying the cell damage. The above antioxi-
dant and hypolipidemic actions of these test fractions are
strongly supported by our previously published reports in
which thymoquinone and limonene showed such strong
effects [19,37]. However, the combined data from in vivo
and in vitro studies strongly suggest that overall alleviation
of ROS related disorders is due to highly effective amelior-
ation of elevated levels of plasma atherogenic TG/TG rich
lipoproteins, highly oxidizable and proatherogenic sd-LDL
subspecies of LDL and low levels of atheroprotective
HDL-C, i.e., lipid triad, coupled with a strong inhibition
of in vivo/ex vivo and in vitro lipid peroxidation through
efficient free radical scavenging properties of the test
fractions and compounds in the order ME extract > pure
thymoquinone > VO extract > pure limonene.
The above discussion conferred that the principal active
constituents thymoquinone, limonene were identified as
antioxidant as well as hypolipidemic agents along with
linoleic acid (ω-6 fatty acid) that shows hypocholesterolemic
activity in the presence of saturated fatty acid, palmitic acid
in the ratio of 27:1, respectively. Thus, a combination of
thymoquinone, limonene and linoleic acid in association
with plamitic acid may be called as compound triad is
highly effective in lipidemic oxidative stress when treated
with ME. VO represented three related active compounds
namely, thymol, thymoquinone and isothymol as antioxi-
dants, they may be termed as thyme triad. VO, despite of
being quite effective in alleviation of hyperlipidemia it
lacks essential fatty acid and reduced form of limonene is
comparatively less active than ME. It is apparently due
to that limonene itself as hypolipidemic, and linoleicacid in the presence of palmitic acid show additive
effects of thymoquinone for removal of lipid by suppression
of HMG-CoA reductase activity and increased levels of
LDL receptor in agreement with Al-Naqeep et al. [48]
consequently resulted in significant decrease in oxida-
tive stress in ME treated rats. Thus, it is clear that most
abundant compound, linoleic acid in ME (Table 1) has
a significant role in controlling the lipid levels and oxi-
dative stress than VO. Because of VO, it showed lack
of reduced form of limonene and absence of linoleic
acid. However, the both test fractions likely share com-
mon mechanisms by suppressing HMG-CoA reductase
activity, increased levels of LDL receptor [48], and free
radical scavenging activity, other active constituents show
independent or synergistic effects to alleviate lipidemic
oxidative stress.
Conclusions
The test fractions, ME and VO having thymoquinone
common to the both extracts, and other pharmaceutical
important compounds effectively ameliorated/normalized
all the CVD risk parameters through modulation of HMG-
CoA reductase activity, levels of LDL receptor and antioxi-
dant mechanisms in atherogenic suspension fed rats. Thus,
ME and VO both can be used as hypolipidemic, antioxi-
dant, antiperoxidative and antiatherogenic agents in CVD
and its complications. In future, it will need to elucidate the
mechanisms of the principal effective compounds and their
additive role of different combinations of the known com-
pounds by GC-MS analysis of ME and VO to exert their
lipid lowering and antioxidant actions, including the vascu-
lar status such as histopathological and plaque load studies
after thorough evaluation study of toxic effect.
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